Background: How to early distinguish the severity of Mycoplasma pneumoniae pneumonia (MPP) is a worldwide concern in clinical practice. We therefore conducted this study to assess the relationship between levels of serum inflammatory chemokines and the severity of MPP. Methods: In this prospective study, we enrolled 39 children with MPP, whose clinical information was collected, blood samples were assayed for cytokines and chemokines by ELISA. Results: The levels of serum CXCL10 in children with severe MPP were significantly higher than those in children with mild MPP (2500.0 [1580.9–2500.0] vs. 675.7 [394.7–1134.9], P < 0.001). Measurement of CXCL10 levels in serum enabled the differentiation of children with severe MPP with an area under the curve (AUC) of 0.885 (95 % CI 0.779–0.991, P < 0.001), with a sensitivity of 81.0 % and a specificity of 83.3 %. Conclusions: Serum CXCL10 level may be a potential biomarker for severe MPP in children.
CITATION STYLE
Li, M., Chen, Y., Li, H., Yang, D., Zhou, Y., Chen, Z., & Zhang, Y. (2021). Serum CXCL10/IP-10 may be a potential biomarker for severe Mycoplasma pneumoniae pneumonia in children. BMC Infectious Diseases, 21(1). https://doi.org/10.1186/s12879-021-06632-4
Mendeley helps you to discover research relevant for your work.